Cetuximab-induced cutaneous toxicity.
作者： H Tomková , M Kohoutek , M Zábojníková , M Pospíšková , L Ostřížková
DOI: 10.1111/J.1468-3083.2009.03490.X
关键词:
摘要: Background Epidermal growth factor receptor inhibitors are recently utilized by oncologists in advanced cases of certain malignancies. However, these agents associated with numerous cutaneous adverse reactions. Objective To systematically review the toxicity cetuximab-treated patients. Methods An analysis a series 24 patients (20 men and 4 women) treated cetuximab (12 head neck cancer 12 colorectal cancer) was performed respect to relevant clinical characteristics. Results A total 22 (91.7%) developed pustular or maculopapular follicular eruption, often referred as acneiform rash. One patient (4.2%) paronychia course therapy. All had combination treatment radiotherapy experienced radiation dermatitis accompanied skin xerosis. Anaphylactic reaction observed three (12.5%). Conclusions The most frequent side effect reported this eruption. authors that all women rash only limited facial involvement, whereas but one man more widespread lesions face, back chest. We found no association between extent severity eruptions (grade 1 vs. grade 2) patients’ response
cabdirect.org
sci-hub.se 参考文章(18)
Ulrich Rodeck, Monika Jost, Csaba Kari, The EGF receptor - an essential regulator of multiple epidermal functions. European Journal of Dermatology. ,vol. 10, pp. 505- 510 ,(2000)
Lillian B. Nanney, Christa M. Stoscheck, Robert A. Underwood, Karen A. Holbrook, Lloyd E. King, Immunolocalization of Epidermal Growth Factor Receptors in Normal Developing Human Skin Journal of Investigative Dermatology. ,vol. 94, pp. 742- 748 ,(1990) , 10.1111/1523-1747.EP12874601
Dominik Peus, Lyn Hamacher, Mark R Pittelkow, EGF-Receptor Tyrosine Kinase Inhibition Induces Keratinocyte Growth Arrest and Terminal Differentiation Journal of Investigative Dermatology. ,vol. 109, pp. 751- 756 ,(1997) , 10.1111/1523-1747.EP12340759
Craig D. Woodworth, Evan Michael, Dan Marker, Sarah Allen, Laura Smith, Matthias Nees, Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment Molecular Cancer Therapeutics. ,vol. 4, pp. 650- 658 ,(2005) , 10.1158/1535-7163.MCT-04-0238
Noushin Heidary, Haley Naik, Susan Burgin, Chemotherapeutic agents and the skin: An update Journal of the American Academy of Dermatology. ,vol. 58, pp. 545- 570 ,(2008) , 10.1016/J.JAAD.2008.01.001
Jenny C. Hu, Parrish Sadeghi, Lauren C. Pinter-Brown, Sharona Yashar, Melvin W. Chiu, Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management Journal of The American Academy of Dermatology. ,vol. 56, pp. 317- 326 ,(2007) , 10.1016/J.JAAD.2006.09.005
E. Van Cutsem, R.J. Mayer, P. Gold, P. Stella, A. Cohn, A. Pippas, P. Windt, P. Molloy, H.J. Lenz, 279 Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin Ejc Supplements. ,vol. 2, pp. 85- 86 ,(2004) , 10.1016/S1359-6349(04)80287-8
K.J. Busam, P. Capodieci, R. Motzer, T. Kiehn, D. Phelan, A.C. Halpern, Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. British Journal of Dermatology. ,vol. 144, pp. 1169- 1176 ,(2001) , 10.1046/J.1365-2133.2001.04226.X
Michele Orditura, Ferdinando De Vita, Gennaro Galizia, Eva Lieto, Loredana Vecchione, Fabiana Vitiello, Erika Martinelli, Fortunato Ciardiello, Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis. Oncology Reports. ,vol. 21, pp. 1023- 1028 ,(2009) , 10.3892/OR_00000319
Caroline Robert, Jean-Charles Soria, Alain Spatz, Axel Le Cesne, David Malka, Patricia Pautier, Janine Wechsler, Catherine Lhomme, Bernard Escudier, Valérie Boige, Jean-Pierre Armand, Thierry Le Chevalier, Cutaneous side-effects of kinase inhibitors and blocking antibodies Lancet Oncology. ,vol. 6, pp. 491- 500 ,(2005) , 10.1016/S1470-2045(05)70243-6